BIO-KEY International convened its Annual Meeting on September 3, 2026, but adjourned it because stockholders failed to approve Proposal 4, which sought authorization to issue up to 1,236,668 shares of common stock upon exercise of warrants from an August 10, 2026 inducement transaction. The meeting is reconvened for October 2, 2026, at the company's Holmdel, New Jersey offices, with no changes to the proposals or polls. BIO-KEY International operates in the biometric security industry, providing fingerprint and facial recognition authentication solutions.

BIO-key International reported Q2 2026 revenues of $1.9 million, a 13% increase year-over-year, driven by a 53% rise in license fee revenue to $1.2 million. Gross margin improved to 87% from 73%, and the net loss narrowed 51% to $(577K). Approximately $0.8 million in hardware revenue was delayed to H2 2026. The company also raised approximately $2.5 million through a warrant exercise at $4.06 per share, bringing cash reserves above $4.5 million. BIO-key operates in the identity and access management (IAM) and biometric authentication technology industry.

BIO-key International, Inc. entered into a warrant exercise agreement with an existing institutional investor to reduce the exercise price of outstanding warrants from $10.20 to $4.06 per share and issue new unregistered warrants for up to 1,236,668 shares at the same reduced price. The transaction generated approximately $2.51 million in gross proceeds, which the company intends to use for working capital and general corporate purposes, including potential repayment of a secured note. Maxim LLC served as the exclusive placement agent, receiving a 5.0% cash fee. The issuance of new warrants is conditioned on stockholder approval at a meeting to be convened within 120 days, with subsequent meetings every 90 days if necessary. BIO-key International operates in the biometric security industry, providing fingerprint and facial recognition technology solutions.

BIO-key International, Inc. announced the engagement of M&K CPAS, PLLC as its new independent registered public accounting firm on July 2, 2026, and the dismissal of Bush & Associates CPA LLC on July 7, 2026. The previous auditor, Bush & Associates, issued audit reports for fiscal years 2024 and 2025 that included an explanatory-paragraph-based qualification regarding the Company's ability to continue as a going concern. BIO-key International, Inc. is a provider of biometric authentication and identity management solutions.

BIO-key International, Inc. announced the reinstatement of trading of its common stock on the Nasdaq Capital Market on July 7, 2026. The company operates in the biometric authentication and identity management industry.

BIO-key International, Inc. received a notice from Nasdaq regarding its failure to file its Quarterly Report on Form 10-Q for the period ended March 31, 2026, which serves as an additional basis for delisting. A hearing with the Nasdaq Hearing Panel is scheduled for June 16, 2026, to consider the continued listing status of compliance with the Periodic Report Rule. BIO-key International, Inc. is a provider of biometric authentication and identity management solutions.